KDR and glioma: Further, gallic acid is known to bind to vascular endothelial growth factor 2 (VEGFR2), which is expressed in tumor vasculature, including GL261 gliomas, but not in healthy vessels, thus enabling tumor vessel targeting and the systemic administration of the nanoclovers.